Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415060 | 1.00 | ERN1 (0.59) | ERN1GPR35TP53CASP6CRHBP | |
| SCHEMBL28669741 | 0.88 | ALDH1A1 (0.64) | ERN1TP53CASP6KMOALDH1A1 | |
| SCHEMBL29386074 | 0.86 | ERN1 (0.57) | ERN1TP53CASP6CRHBPCRHR2 | |
| SCHEMBL2404465 | 0.86 | ERN1 (0.57) | ERN1TP53CASP6CRHBPCRHR2 | |
| SCHEMBL2403547 | 0.85 | GPR35 (0.55) | ERN1GPR35CASP6ALDH1A1TDP1 | |
| SCHEMBL13482044 | 0.84 | ERN1 (0.51) | ERN1TP53CASP6KMOALDH1A1 | |
| SCHEMBL3360547 | 0.83 | ERN1 (0.57) | ERN1TP53CASP6CRHBPCRHR2 | |
| SCHEMBL3360693 | 0.83 | ERN1 (0.57) | ERN1GPR35TP53CASP6CRHBP | |
| SCHEMBL5605382 | 0.82 | TDP1 (0.69) | ERN1GPR35CASP6CRHBPCRHR2 | |
| Bromide SCHEMBL3516464 | 0.82 | ERN1 (0.56) | ERN1TP53CASP6CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| WO-2021001044-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2021-01-07 | — | — | WO | disclosed |
| US-20170275255-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | HETERO RESEARCH FOUNDATION (IN) | 2017-09-28 | — | — | US | disclosed |
| US-20170275255-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | HETERO RESEARCH FOUNDATION (IN) | 2017-09-28 | — | — | US | disclosed |
| US-9440927-B2 | Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-9440927-B2 | Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| CN-104592033-A | Synthetic method of promacta key intermediate | HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| EP-2865662-A1 | Process for the preparation of a thrombopoietin agonist | Dipharma Francis S.r.l. (IT) | 2015-04-29 | — | — | EP | disclosed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20150087845-A1 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | GLENMARK GENERICS LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20040077855-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1370252-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1351979-A1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002085343-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002057300-A1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077855-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | ERN1 4585/4885GPR35 2375/4885TP53 2015/4885 |
| US-20040053299-A1 | Regulated activation of cell-membrane receptors by metal-chelating agonists | CASR, TRPM8, TRPM6 | ERN1 3391/4885GPR35 390/4885TP53 1615/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885GPR35 2399/4885TP53 2566/4885 |
| US-20170275255-A1 | CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID | ACKR3, PLG, GCG | ERN1 1286/4885GPR35 1326/4885TP53 3034/4885 |
| US-20150087845-A1 | PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS | CYP3A5, UGT1A3, HPD | ERN1 4747/4885GPR35 2110/4885TP53 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.